CG Oncology CGON Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | ||
|---|---|---|---|---|---|
| Revenue (Gross) by Product | |||||
| Commercial And Development Revenue | $4.3M+33.1% | $3.23M+114% | $1.51M— | $0— | |
| License And Collaboration Revenue | $768K-4.7% | $806K+21.0% | $666K+20.9% | $551K+170% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does CG Oncology break its business down?
- CG Oncology (CGON) reports revenue (gross) by product across 2 parts — Commercial And Development Revenue and License And Collaboration Revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does CG Oncology's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in CG Oncology's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.